EGFR and liver cancer: Agents targeting epidermal growth factor receptor (EGFR), mainly including tyrosine kinase inhibitors (TKIs), such as sorafenib or lenvatinib, have been approved as first-line drugs for the treatment of advanced liver cancer (3–6).